董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric Schlorff | 男 | Chief Executive Officer and Director | 53 | 40.65万美元 | 0.63 | 2026-05-07 |
| Kenneth Van Heel | 男 | Director | 62 | 4.57万美元 | 0.47 | 2026-05-07 |
| Jennifer A. Baird | 女 | Chair of the Board and Director | 58 | 5.64万美元 | 0.27 | 2026-05-07 |
| John Neuman | 男 | Director | 60 | 3.43万美元 | 0.83 | 2026-05-07 |
| Bernadette N. Vincent | 女 | Director | 67 | 2.61万美元 | 0.03 | 2026-05-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Messinger | 男 | Chief Financial Officer | 51 | 3.00万美元 | 0.18 | 2026-05-07 |
| Eric Schlorff | 男 | Chief Executive Officer and Director | 53 | 40.65万美元 | 0.63 | 2026-05-07 |
| Kevin Chung | 男 | Chief Medical Officer | 53 | 36.75万美元 | 0.41 | 2026-05-07 |
董事简历
中英对照 | 中文 | 英文- Eric Schlorff
-
Eric Schlorff自2019年7月起担任SeaStar Medical董事兼首席执行官，并于2019年3月至2019年7月担任首席运营官。Schlorff先生还曾于2016年6月至2019年5月担任SeaStar Medical董事。1999年至2019年，Schlorff先生在密歇根州米德兰和印第安纳州印第安纳波利斯的陶氏化学公司担任多个职务。2016年6月至2019年2月，Schlorff先生担任陶氏化学养老金计划另类投资全球总监，并于2013年6月至2016年6月担任陶氏农业科学公司作物保护和种子全球财务负责人。施勒夫先生担任的其他领导职务包括：陶氏益农的全球市场情报主管、陶氏益农的特许权使用费全球财务经理、陶氏化学公司的另类投资高级投资经理、陶氏化学公司的制药新业务发展、陶氏化学公司新业务部门的全球财务分析师、陶氏化学公司的陶氏益农的全球财务分析师。
Eric Schlorff has served as a director and the Chief Executive Officer of SeaStar since July 2019 and as Chief Operating Officer from March 2019 to July 2019. Mr. Schlorff also previously served as a Director of SeaStar from June 2016 to May 2019. From 1999 to 2019, Mr. Schlorff served in multiple roles at The Dow Chemical Company in Midland, Michigan and Indianapolis, Indiana. From June 2016 to February 2019, Mr. Schlorff served as Global Director of Alternative Investments for The Dow Chemical Pension Plan, and Global Finance Leader for Crop Protection & Seeds at Dow AgroSciences from June 2013 to June 2016. Additional leadership positions held by Mr. Schlorff include the Global Market Intelligence Leader at Dow AgroSciences, Global Financial Manager of Royalties at Dow AgroSciences, Senior Investment Manager of Alternative Investments at The Dow Chemical Company, New Business Development of Pharmaceuticals at The Dow Chemical Company, Global Financial Analyst within the New Businesses division at The Dow Chemical Company, and Global Financial Analyst within Dow AgroSciences at The Dow Chemical Company. - Eric Schlorff自2019年7月起担任SeaStar Medical董事兼首席执行官，并于2019年3月至2019年7月担任首席运营官。Schlorff先生还曾于2016年6月至2019年5月担任SeaStar Medical董事。1999年至2019年，Schlorff先生在密歇根州米德兰和印第安纳州印第安纳波利斯的陶氏化学公司担任多个职务。2016年6月至2019年2月，Schlorff先生担任陶氏化学养老金计划另类投资全球总监，并于2013年6月至2016年6月担任陶氏农业科学公司作物保护和种子全球财务负责人。施勒夫先生担任的其他领导职务包括：陶氏益农的全球市场情报主管、陶氏益农的特许权使用费全球财务经理、陶氏化学公司的另类投资高级投资经理、陶氏化学公司的制药新业务发展、陶氏化学公司新业务部门的全球财务分析师、陶氏化学公司的陶氏益农的全球财务分析师。
- Eric Schlorff has served as a director and the Chief Executive Officer of SeaStar since July 2019 and as Chief Operating Officer from March 2019 to July 2019. Mr. Schlorff also previously served as a Director of SeaStar from June 2016 to May 2019. From 1999 to 2019, Mr. Schlorff served in multiple roles at The Dow Chemical Company in Midland, Michigan and Indianapolis, Indiana. From June 2016 to February 2019, Mr. Schlorff served as Global Director of Alternative Investments for The Dow Chemical Pension Plan, and Global Finance Leader for Crop Protection & Seeds at Dow AgroSciences from June 2013 to June 2016. Additional leadership positions held by Mr. Schlorff include the Global Market Intelligence Leader at Dow AgroSciences, Global Financial Manager of Royalties at Dow AgroSciences, Senior Investment Manager of Alternative Investments at The Dow Chemical Company, New Business Development of Pharmaceuticals at The Dow Chemical Company, Global Financial Analyst within the New Businesses division at The Dow Chemical Company, and Global Financial Analyst within Dow AgroSciences at The Dow Chemical Company.
- Kenneth Van Heel
-
Kenneth Van Heel，自2021年起担任SeaStar Medical董事，此前曾于2011年至2015年担任董事。自2021年11月起，Van Heel先生还担任卡车和运输行业软件提供商Motorcity Systems的首席执行官。自2012年6月以来，Van Heel先生还担任农业产品生物技术公司Gantec，Inc.的董事和顾问。从2019年6月至2021年6月，Van Heel先生担任Motorcity Systems的顾问。在加入Motorcity Systems之前，Van Heel先生曾在陶氏化学公司担任过各种职务。在陶氏化学公司，从2016年到2021年，Van Heel先生担任全球战略规划总监；从2012年到2016年，Van Heel先生担任另类投资和CIO加拿大养老金计划总监；从2006年到2016年，Van Heel先生担任另类投资总监；从2003年到2006年，Van Heel先生担任私募股权高级经理；从2000年到2003年，Van Heel先生担任陶氏企业风险投资经理；从1986年到2000年，Van Heel先生在风险投资和业务发展部门担任过各种职务。
Kenneth Van Heel has served as a director of SeaStar since 2021 and previously served as a director from 2011 to 2015. Mr. Van Heel has also served as Chief Executive Officer at Motorcity Systems, a software provider in the trucking and transportation industry, since November 2021. Since June 2012, Mr. Van Heel has also served as a Director and Advisor at Gantec, Inc., a biotechnology company for agricultural products through April 2025. Prior to joining Motorcity Systems, Mr. Van Heel served in various roles at The Dow Chemical Company. At The Dow Chemical Company, from 2016 to 2021, Mr. Van Heel served as the Global Director of Strategic Planning; from 2012 to 2016, Mr. Van Heel served as the Director of Alternative Investments and CIO Canadian Pension Plan; from 2006 to 2016, Mr. Van Heel served as Director of Alternative Investments; from 2003 to 2006, Mr. Van Heel served as the Senior Manager of Private Equity; from 2000 to 2003, Mr. Van Heel served as the Manager of Dow Corporate Venture Capital; and from 1986 to 2000, Mr. Van Heel held various positions within the Ventures and Business Development division. - Kenneth Van Heel，自2021年起担任SeaStar Medical董事，此前曾于2011年至2015年担任董事。自2021年11月起，Van Heel先生还担任卡车和运输行业软件提供商Motorcity Systems的首席执行官。自2012年6月以来，Van Heel先生还担任农业产品生物技术公司Gantec，Inc.的董事和顾问。从2019年6月至2021年6月，Van Heel先生担任Motorcity Systems的顾问。在加入Motorcity Systems之前，Van Heel先生曾在陶氏化学公司担任过各种职务。在陶氏化学公司，从2016年到2021年，Van Heel先生担任全球战略规划总监；从2012年到2016年，Van Heel先生担任另类投资和CIO加拿大养老金计划总监；从2006年到2016年，Van Heel先生担任另类投资总监；从2003年到2006年，Van Heel先生担任私募股权高级经理；从2000年到2003年，Van Heel先生担任陶氏企业风险投资经理；从1986年到2000年，Van Heel先生在风险投资和业务发展部门担任过各种职务。
- Kenneth Van Heel has served as a director of SeaStar since 2021 and previously served as a director from 2011 to 2015. Mr. Van Heel has also served as Chief Executive Officer at Motorcity Systems, a software provider in the trucking and transportation industry, since November 2021. Since June 2012, Mr. Van Heel has also served as a Director and Advisor at Gantec, Inc., a biotechnology company for agricultural products through April 2025. Prior to joining Motorcity Systems, Mr. Van Heel served in various roles at The Dow Chemical Company. At The Dow Chemical Company, from 2016 to 2021, Mr. Van Heel served as the Global Director of Strategic Planning; from 2012 to 2016, Mr. Van Heel served as the Director of Alternative Investments and CIO Canadian Pension Plan; from 2006 to 2016, Mr. Van Heel served as Director of Alternative Investments; from 2003 to 2006, Mr. Van Heel served as the Senior Manager of Private Equity; from 2000 to 2003, Mr. Van Heel served as the Manager of Dow Corporate Venture Capital; and from 1986 to 2000, Mr. Van Heel held various positions within the Ventures and Business Development division.
- Jennifer A. Baird
-
Jennifer A. Baird自2024年6月起担任SeaStar董事，自2025年起担任董事会主席。自2023年以来，Baird女士一直担任Culturewell，Co.的董事会执行主席，该组织通过环境采样测试和细菌风险评估，为医疗保健感染预防提供可操作的见解。2017年至2022年，Baird女士创立了Fifth Eye Inc.并担任其首席执行官，该公司是一家受FDA监管的软件医疗设备公司，使用流式生理参数输入开发和商业化医疗保健相关的临床算法和预测分析（已被Airstrip Technologies，Inc.收购）。2010年至2017年，Baird女士担任Accio Energy，Inc.的首席执行官，该公司是一家专注于开发转型可再生能源技术的组织。此外，Baird女士还与他人共同创立了其他基于医疗保健的公司，包括Accuri Cytometers，Inc.（已被Becton Dickinson收购）和Sonetics Ultrasound，Inc.。Baird女士曾在Fifth Eye，Inc.、Accio Energy，Inc.、Accuri Cytometers Inc.和Sonetics Ultrasound，Inc.各自担任首席执行官董事职务。Baird女士自2009年起担任非营利组织Hope Clinic的董事。Baird女士拥有密歇根大学组织心理学/领导力文学士学位和西北大学管理研究生院家乐氏工商管理硕士学位。Baird女士获得NACD董事认证2025年。
Jennifer A. Baird has served as a director of SeaStar since June 2024 and as Chair of the Board since 2025. Since 2023, Ms. Baird has served as the Executive Chair of the Board of Directors for Culturewell, Co., an organization that delivers actionable insights for healthcare infection prevention through environmental sampling testing and germ risk assessments. From 2017 to 2022, Ms. Baird founded and served as the Chief Executive Officer of Fifth Eye Inc., an FDA regulated software medical device company developing and commercializing healthcare related clinical algorithms and predictive analytics using streaming physiologic parameter inputs (acquired by Airstrip Technologies, Inc.). From 2010 to 2017, Ms. Baird was the Chief Executive Officer of Accio Energy, Inc., an organization that focused on developing transformational renewable energy technology. In addition, Ms. Baird has co founded other healthcare based companies, including Accuri Cytometers, Inc. (acquired by Becton Dickinson) and Sonetics Ultrasound, Inc. Ms. Baird served in Chief Executive Officer director roles for each of Fifth Eye, Inc., Accio Energy, Inc., Accuri Cytometers Inc., and Sonetics Ultrasound, Inc. Ms. Baird has served as a director for Hope Clinic, a nonprofit, since 2009. Ms. Baird has a Bacelor of Arts in Organizational Psychology/Leadership from the University of Michigan and a Master of Business Administration from Kellogg Graduate School of Management Northwestern University. Ms. Baird became NACD Directorship Certified in 2025. - Jennifer A. Baird自2024年6月起担任SeaStar董事，自2025年起担任董事会主席。自2023年以来，Baird女士一直担任Culturewell，Co.的董事会执行主席，该组织通过环境采样测试和细菌风险评估，为医疗保健感染预防提供可操作的见解。2017年至2022年，Baird女士创立了Fifth Eye Inc.并担任其首席执行官，该公司是一家受FDA监管的软件医疗设备公司，使用流式生理参数输入开发和商业化医疗保健相关的临床算法和预测分析（已被Airstrip Technologies，Inc.收购）。2010年至2017年，Baird女士担任Accio Energy，Inc.的首席执行官，该公司是一家专注于开发转型可再生能源技术的组织。此外，Baird女士还与他人共同创立了其他基于医疗保健的公司，包括Accuri Cytometers，Inc.（已被Becton Dickinson收购）和Sonetics Ultrasound，Inc.。Baird女士曾在Fifth Eye，Inc.、Accio Energy，Inc.、Accuri Cytometers Inc.和Sonetics Ultrasound，Inc.各自担任首席执行官董事职务。Baird女士自2009年起担任非营利组织Hope Clinic的董事。Baird女士拥有密歇根大学组织心理学/领导力文学士学位和西北大学管理研究生院家乐氏工商管理硕士学位。Baird女士获得NACD董事认证2025年。
- Jennifer A. Baird has served as a director of SeaStar since June 2024 and as Chair of the Board since 2025. Since 2023, Ms. Baird has served as the Executive Chair of the Board of Directors for Culturewell, Co., an organization that delivers actionable insights for healthcare infection prevention through environmental sampling testing and germ risk assessments. From 2017 to 2022, Ms. Baird founded and served as the Chief Executive Officer of Fifth Eye Inc., an FDA regulated software medical device company developing and commercializing healthcare related clinical algorithms and predictive analytics using streaming physiologic parameter inputs (acquired by Airstrip Technologies, Inc.). From 2010 to 2017, Ms. Baird was the Chief Executive Officer of Accio Energy, Inc., an organization that focused on developing transformational renewable energy technology. In addition, Ms. Baird has co founded other healthcare based companies, including Accuri Cytometers, Inc. (acquired by Becton Dickinson) and Sonetics Ultrasound, Inc. Ms. Baird served in Chief Executive Officer director roles for each of Fifth Eye, Inc., Accio Energy, Inc., Accuri Cytometers Inc., and Sonetics Ultrasound, Inc. Ms. Baird has served as a director for Hope Clinic, a nonprofit, since 2009. Ms. Baird has a Bacelor of Arts in Organizational Psychology/Leadership from the University of Michigan and a Master of Business Administration from Kellogg Graduate School of Management Northwestern University. Ms. Baird became NACD Directorship Certified in 2025.
- John Neuman
-
John Neuman自2024年6月起担任SeaStar的董事。Neuman先生，在服务30年后于2023年从陶氏化学公司（“陶氏”）退休。他从陶氏全球财务会计副总裁的职位上退休，领导着一支由350多名团队成员组成的全球团队。他所在的组织负责确保一个由全球400多家法人实体组成的网络高效、准确地进行财务核算和报告，包括准备向美国证券交易委员会提交财务文件。此外，Neuman先生为公司财务总监和孟买全球会计提供监督和指导。他于1993年加入陶氏，曾在财务部门担任多个职位，包括公司审计、公司控制人、商业财务和控制人。他的商业财务角色包括在瑞士执行为期五年的国际任务。他在陶氏的任期内负责多项并购交易的财务整合和报告职责，包括罗门哈斯和陶氏康宁的收购以及陶氏杜邦的合并。在加入陶氏之前，Neuman先生曾在Deloitte & Touche LLP担任审计经理。他拥有密歇根州立大学会计学学位，注册会计师，曾担任密歇根州立大学会计和信息系统系外部顾问委员会成员。
John Neuman has served as a director of SeaStar since June 2024. Mr. Neuman, retired from Dow Chemical Company ("Dow") in 2023 following 30 years of service. He retired as Vice President of Global Financial Accounting at Dow, directing a global team of more than 350 team members. His organization was responsible for ensuring efficient and accurate financial accounting and reporting for a network of more than 400 legal entities across the globe including preparing the financial filings with the U.S. Securities and Exchange Commission. Additionally, Mr. Neuman provided oversight and direction for Corporate Controllers and for Mumbai Global Accounting. He joined Dow in 1993, and held various positions in Finance, including roles in corporate auditing, corporate controllers, business finance and controllers. His business finance role included a five year international assignment in Switzerland. His tenure at Dow included finance integration and reporting responsibilities for several M&A transactions, including the Rohm & Haas and Dow Corning acquisitions and the DowDuPont merger. Prior to joining Dow, Mr. Neuman worked as an audit manager for Deloitte & Touche LLP. He holds a degree in accounting from Michigan State University, is a CPA, and has served as a member of the MSU External Advisory Board for the Department of Accounting and Information Systems. - John Neuman自2024年6月起担任SeaStar的董事。Neuman先生，在服务30年后于2023年从陶氏化学公司（“陶氏”）退休。他从陶氏全球财务会计副总裁的职位上退休，领导着一支由350多名团队成员组成的全球团队。他所在的组织负责确保一个由全球400多家法人实体组成的网络高效、准确地进行财务核算和报告，包括准备向美国证券交易委员会提交财务文件。此外，Neuman先生为公司财务总监和孟买全球会计提供监督和指导。他于1993年加入陶氏，曾在财务部门担任多个职位，包括公司审计、公司控制人、商业财务和控制人。他的商业财务角色包括在瑞士执行为期五年的国际任务。他在陶氏的任期内负责多项并购交易的财务整合和报告职责，包括罗门哈斯和陶氏康宁的收购以及陶氏杜邦的合并。在加入陶氏之前，Neuman先生曾在Deloitte & Touche LLP担任审计经理。他拥有密歇根州立大学会计学学位，注册会计师，曾担任密歇根州立大学会计和信息系统系外部顾问委员会成员。
- John Neuman has served as a director of SeaStar since June 2024. Mr. Neuman, retired from Dow Chemical Company ("Dow") in 2023 following 30 years of service. He retired as Vice President of Global Financial Accounting at Dow, directing a global team of more than 350 team members. His organization was responsible for ensuring efficient and accurate financial accounting and reporting for a network of more than 400 legal entities across the globe including preparing the financial filings with the U.S. Securities and Exchange Commission. Additionally, Mr. Neuman provided oversight and direction for Corporate Controllers and for Mumbai Global Accounting. He joined Dow in 1993, and held various positions in Finance, including roles in corporate auditing, corporate controllers, business finance and controllers. His business finance role included a five year international assignment in Switzerland. His tenure at Dow included finance integration and reporting responsibilities for several M&A transactions, including the Rohm & Haas and Dow Corning acquisitions and the DowDuPont merger. Prior to joining Dow, Mr. Neuman worked as an audit manager for Deloitte & Touche LLP. He holds a degree in accounting from Michigan State University, is a CPA, and has served as a member of the MSU External Advisory Board for the Department of Accounting and Information Systems.
- Bernadette N. Vincent
-
Bernadette N. Vincent自2024年6月起担任SeaStar的董事。Vincent女士目前是WC Operations，LLC，（d.b.a.，Winners Circle Group of Texas）的首席执行官，该公司是一家行为健康组织，为有特殊需要的儿童、成年人及其家人提供服务。自2024年以来，她还一直担任WC Operations，LLC的董事会成员。Vincent女士曾在Satellite Healthcare Inc.担任多个职务，该公司是一家全国性的非营利性肾脏护理公司，提供治疗方案教育、应用实用研究和临床试验以及慢性、家庭和急性透析疗法，包括2021年至2023年担任总裁兼首席运营官，2020年至2021年担任首席运营官，2018年至2020年担任首席外勤运营官。在此之前的2015年至2017年，Vincent女士曾在多个部门任职，担任Mednax, Inc.的首席运营官，该公司是一家提供多专科医师和健康系统服务的全国性医疗集团。在此之前，Vincent女士曾在费森尤斯医疗北美公司担任过各种领导职务。她从2008年至2014年担任集团副总裁，负责监督美国东南部地区的急性、慢性和家庭透析业务。她从2006年至2008年担任运营副总裁，并被选中参与哈佛商学院和欧洲工商管理学院的多个高级领导力发展项目。她还与费森尤斯医疗的研究部门合作，监督了她所在地区针对终末期肾病护理人群进行的临床试验。Vincent女士的董事会经历跨越了2014年至2023年，她于2018年至2023年担任Satellite Healthcare Inc.的无投票权董事会成员，在质量、安全和患者体验；政府与薪酬、执行与战略委员会任职。Vincent女士自2021年起担任美国国家肾脏基金会、加利福尼亚州和太平洋西北分会的董事，并于2014年至2015年担任桂冠学院特许学校的创始人董事会成员，在财务委员会任职。Vincent女士拥有迪拉德大学护理学学士学位和佩珀代因大学工商管理硕士学位。
Bernadette N. Vincent has served as a director of SeaStar since June 2024. Ms. Vincent is currently CEO of WC Operations, LLC, (d.b.a., Winners Circle Group of Texas), a behavioral health organization that serves special needs children, adults and their families. She has also served on the Board of WC Operations, LLC since 2024. Ms Vincent served in various roles at Satellite Healthcare Inc., a national non profit kidney care company offering treatment options education, applied pragmatic research and clinical trials, and chronic, home and acute dialysis therapies, including as President & Chief Operating Officer from 2021 to 2023, as Chief Operating Officer from 2020 to 2021, and as Chief Field Operations Officer from 2018 to 2020. Prior to that from 2015 to 2017, Ms. Vincent served in various divisions as Chief Operating Officer for Mednax, Inc., a national medical group providing multi specialty physician and health system services company. Prior to that, Ms. Vincent served in various leadership roles with Fresenius Medical Care North America. She was Group Vice President from 2008 2014, overseeing Acute, Chronic and Home Dialysis operations over the southeastern part of the United States. She served as Vice President of Operations from 2006 2008 and was a selected to participate in several advanced leadership development programs at Harvard Business School and INSEAD. She also oversaw clinical trials throughout her regions for End Stage Kidney Disease Care Populations, working with the Research Division of Fresenius Medical Care. Ms. Vincent's Board of Directors experience spanned from 2014 2023, where she served from 2018 to 2023, as a non voting Board member for Satellite Healthcare Inc., serving on the Quality, Safety & Patient Experience; Government & Compensation, Executive & Strategy committees. Ms. Vincent served as a director for the National Kidney Foundation, California & Pacific Northwest chapter since 2021, and was Founder Board member for the Laureate Academy Charter School from 2014 to 2015, serving on the Finance Committee. Ms. Vincent holds a Bachelor of Science in Nursing from Dillard University and Master of Business Administration from Pepperdine University. - Bernadette N. Vincent自2024年6月起担任SeaStar的董事。Vincent女士目前是WC Operations，LLC，（d.b.a.，Winners Circle Group of Texas）的首席执行官，该公司是一家行为健康组织，为有特殊需要的儿童、成年人及其家人提供服务。自2024年以来，她还一直担任WC Operations，LLC的董事会成员。Vincent女士曾在Satellite Healthcare Inc.担任多个职务，该公司是一家全国性的非营利性肾脏护理公司，提供治疗方案教育、应用实用研究和临床试验以及慢性、家庭和急性透析疗法，包括2021年至2023年担任总裁兼首席运营官，2020年至2021年担任首席运营官，2018年至2020年担任首席外勤运营官。在此之前的2015年至2017年，Vincent女士曾在多个部门任职，担任Mednax, Inc.的首席运营官，该公司是一家提供多专科医师和健康系统服务的全国性医疗集团。在此之前，Vincent女士曾在费森尤斯医疗北美公司担任过各种领导职务。她从2008年至2014年担任集团副总裁，负责监督美国东南部地区的急性、慢性和家庭透析业务。她从2006年至2008年担任运营副总裁，并被选中参与哈佛商学院和欧洲工商管理学院的多个高级领导力发展项目。她还与费森尤斯医疗的研究部门合作，监督了她所在地区针对终末期肾病护理人群进行的临床试验。Vincent女士的董事会经历跨越了2014年至2023年，她于2018年至2023年担任Satellite Healthcare Inc.的无投票权董事会成员，在质量、安全和患者体验；政府与薪酬、执行与战略委员会任职。Vincent女士自2021年起担任美国国家肾脏基金会、加利福尼亚州和太平洋西北分会的董事，并于2014年至2015年担任桂冠学院特许学校的创始人董事会成员，在财务委员会任职。Vincent女士拥有迪拉德大学护理学学士学位和佩珀代因大学工商管理硕士学位。
- Bernadette N. Vincent has served as a director of SeaStar since June 2024. Ms. Vincent is currently CEO of WC Operations, LLC, (d.b.a., Winners Circle Group of Texas), a behavioral health organization that serves special needs children, adults and their families. She has also served on the Board of WC Operations, LLC since 2024. Ms Vincent served in various roles at Satellite Healthcare Inc., a national non profit kidney care company offering treatment options education, applied pragmatic research and clinical trials, and chronic, home and acute dialysis therapies, including as President & Chief Operating Officer from 2021 to 2023, as Chief Operating Officer from 2020 to 2021, and as Chief Field Operations Officer from 2018 to 2020. Prior to that from 2015 to 2017, Ms. Vincent served in various divisions as Chief Operating Officer for Mednax, Inc., a national medical group providing multi specialty physician and health system services company. Prior to that, Ms. Vincent served in various leadership roles with Fresenius Medical Care North America. She was Group Vice President from 2008 2014, overseeing Acute, Chronic and Home Dialysis operations over the southeastern part of the United States. She served as Vice President of Operations from 2006 2008 and was a selected to participate in several advanced leadership development programs at Harvard Business School and INSEAD. She also oversaw clinical trials throughout her regions for End Stage Kidney Disease Care Populations, working with the Research Division of Fresenius Medical Care. Ms. Vincent's Board of Directors experience spanned from 2014 2023, where she served from 2018 to 2023, as a non voting Board member for Satellite Healthcare Inc., serving on the Quality, Safety & Patient Experience; Government & Compensation, Executive & Strategy committees. Ms. Vincent served as a director for the National Kidney Foundation, California & Pacific Northwest chapter since 2021, and was Founder Board member for the Laureate Academy Charter School from 2014 to 2015, serving on the Finance Committee. Ms. Vincent holds a Bachelor of Science in Nursing from Dillard University and Master of Business Administration from Pepperdine University.
高管简历
中英对照 | 中文 | 英文- Michael Messinger
Michael Messinger，注册会计师。他目前是财务的副总裁。他在金融、会计和临床发展预测中拥有超过15年的经验。加入ContraFect之前，他曾担任Coelacanth Corporation和Lexicon Pharmaceuticals, Inc.的财务总监五年（在他担任Lexicon财务总监八年之后）。从2007年6月到2012年11月他加入ContraFect，他负责Lexicon和Symphony Capital, LLC的财务管理（除了协调与Lexicon发展项目有关财政政策和项目管理之外）。他获得Michigan大学的会计学学士学位。他在Ernst & Young开始他的职业生涯，担任审计员。
Michael Messinger has served as Chief Financial Officer since November 14, 2025. Mr. Messinger has more than two decades of experience and leadership in financing and accounting for drug discovery and development organizations. He has served as a member of the board of directors of Filament Health Corp. since March 2024 and a strategic consultant to various biotechnology companies since January of 2024. Mr. Messinger most recently served as Chief Financial Officer of ContraFect Corporation, a biotechnology company focused on treatments for life threatening bacterial infections in the hospital setting, from October 2018 to November 2023, where he led the company through multiple financing rounds, including investments from Pfizer Inc., and a contract with BARDA (Biomedical Advanced Research and Development Authority). Prior to becoming the Chief Financial Officer of ContraFect, Mr. Messinger held senior financial roles at ContraFect, Lexicon Pharmaceuticals, Inc. and Coelacanth Corporation. He started his career as an auditor at Ernst & Young LLP. Mr. Messinger received his B.B.A. degree in accounting from the University of Michigan.- Michael Messinger，注册会计师。他目前是财务的副总裁。他在金融、会计和临床发展预测中拥有超过15年的经验。加入ContraFect之前，他曾担任Coelacanth Corporation和Lexicon Pharmaceuticals, Inc.的财务总监五年（在他担任Lexicon财务总监八年之后）。从2007年6月到2012年11月他加入ContraFect，他负责Lexicon和Symphony Capital, LLC的财务管理（除了协调与Lexicon发展项目有关财政政策和项目管理之外）。他获得Michigan大学的会计学学士学位。他在Ernst & Young开始他的职业生涯，担任审计员。
- Michael Messinger has served as Chief Financial Officer since November 14, 2025. Mr. Messinger has more than two decades of experience and leadership in financing and accounting for drug discovery and development organizations. He has served as a member of the board of directors of Filament Health Corp. since March 2024 and a strategic consultant to various biotechnology companies since January of 2024. Mr. Messinger most recently served as Chief Financial Officer of ContraFect Corporation, a biotechnology company focused on treatments for life threatening bacterial infections in the hospital setting, from October 2018 to November 2023, where he led the company through multiple financing rounds, including investments from Pfizer Inc., and a contract with BARDA (Biomedical Advanced Research and Development Authority). Prior to becoming the Chief Financial Officer of ContraFect, Mr. Messinger held senior financial roles at ContraFect, Lexicon Pharmaceuticals, Inc. and Coelacanth Corporation. He started his career as an auditor at Ernst & Young LLP. Mr. Messinger received his B.B.A. degree in accounting from the University of Michigan.
- Eric Schlorff
Eric Schlorff自2019年7月起担任SeaStar Medical董事兼首席执行官，并于2019年3月至2019年7月担任首席运营官。Schlorff先生还曾于2016年6月至2019年5月担任SeaStar Medical董事。1999年至2019年，Schlorff先生在密歇根州米德兰和印第安纳州印第安纳波利斯的陶氏化学公司担任多个职务。2016年6月至2019年2月，Schlorff先生担任陶氏化学养老金计划另类投资全球总监，并于2013年6月至2016年6月担任陶氏农业科学公司作物保护和种子全球财务负责人。施勒夫先生担任的其他领导职务包括：陶氏益农的全球市场情报主管、陶氏益农的特许权使用费全球财务经理、陶氏化学公司的另类投资高级投资经理、陶氏化学公司的制药新业务发展、陶氏化学公司新业务部门的全球财务分析师、陶氏化学公司的陶氏益农的全球财务分析师。
Eric Schlorff has served as a director and the Chief Executive Officer of SeaStar since July 2019 and as Chief Operating Officer from March 2019 to July 2019. Mr. Schlorff also previously served as a Director of SeaStar from June 2016 to May 2019. From 1999 to 2019, Mr. Schlorff served in multiple roles at The Dow Chemical Company in Midland, Michigan and Indianapolis, Indiana. From June 2016 to February 2019, Mr. Schlorff served as Global Director of Alternative Investments for The Dow Chemical Pension Plan, and Global Finance Leader for Crop Protection & Seeds at Dow AgroSciences from June 2013 to June 2016. Additional leadership positions held by Mr. Schlorff include the Global Market Intelligence Leader at Dow AgroSciences, Global Financial Manager of Royalties at Dow AgroSciences, Senior Investment Manager of Alternative Investments at The Dow Chemical Company, New Business Development of Pharmaceuticals at The Dow Chemical Company, Global Financial Analyst within the New Businesses division at The Dow Chemical Company, and Global Financial Analyst within Dow AgroSciences at The Dow Chemical Company.- Eric Schlorff自2019年7月起担任SeaStar Medical董事兼首席执行官，并于2019年3月至2019年7月担任首席运营官。Schlorff先生还曾于2016年6月至2019年5月担任SeaStar Medical董事。1999年至2019年，Schlorff先生在密歇根州米德兰和印第安纳州印第安纳波利斯的陶氏化学公司担任多个职务。2016年6月至2019年2月，Schlorff先生担任陶氏化学养老金计划另类投资全球总监，并于2013年6月至2016年6月担任陶氏农业科学公司作物保护和种子全球财务负责人。施勒夫先生担任的其他领导职务包括：陶氏益农的全球市场情报主管、陶氏益农的特许权使用费全球财务经理、陶氏化学公司的另类投资高级投资经理、陶氏化学公司的制药新业务发展、陶氏化学公司新业务部门的全球财务分析师、陶氏化学公司的陶氏益农的全球财务分析师。
- Eric Schlorff has served as a director and the Chief Executive Officer of SeaStar since July 2019 and as Chief Operating Officer from March 2019 to July 2019. Mr. Schlorff also previously served as a Director of SeaStar from June 2016 to May 2019. From 1999 to 2019, Mr. Schlorff served in multiple roles at The Dow Chemical Company in Midland, Michigan and Indianapolis, Indiana. From June 2016 to February 2019, Mr. Schlorff served as Global Director of Alternative Investments for The Dow Chemical Pension Plan, and Global Finance Leader for Crop Protection & Seeds at Dow AgroSciences from June 2013 to June 2016. Additional leadership positions held by Mr. Schlorff include the Global Market Intelligence Leader at Dow AgroSciences, Global Financial Manager of Royalties at Dow AgroSciences, Senior Investment Manager of Alternative Investments at The Dow Chemical Company, New Business Development of Pharmaceuticals at The Dow Chemical Company, Global Financial Analyst within the New Businesses division at The Dow Chemical Company, and Global Financial Analyst within Dow AgroSciences at The Dow Chemical Company.
- Kevin Chung
Kevin Chung，自2022年7月1日起担任海星医疗首席医疗官。钟博士于2016年至2022年担任Health Sciences军校医学系教授，并自2018年起担任医学系主任。从2014年到2020年，郑博士担任美国外科医生的重症监护顾问。从2016年到2018年，钟博士在布鲁克陆军医疗中心担任医学部主任。2015年至2016年，Chung博士担任美国陆军外科研究所研究主任，2012年至2015年担任临床试验任务区经理。从2006年到2013年，郑博士担任美国陆军烧伤中心烧伤重症监护室的医疗主任。Chung博士是一名退役陆军上校，在德克萨斯州和马里兰州持有行医执照。
Kevin Chung has served as the Chief Medical Officer of SeaStar since July 1, 2022. Dr. Chung served as a professor in the Department of Medicine at the Uniformed Services University of the Health Sciences from 2016 to 2022, and as Chair of the Department of Medicine since 2018. From 2014 to 2020, Dr. Chung served as Critical Care Consultant to the U.S. Surgeon General. From 2016 to 2018, Dr. Chung served as Department of Medicine Chief at the Brooke Army Medical Center. From 2015 to 2016, Dr. Chung served as Director of Research at the US Army Institute of Surgical Research, and as Task Area Manager, Clinical Trial from 2012 to 2015. From 2006 to 2013, Dr. Chung served as Medical Director, Burn Intensive Care Unit at the US Army Burn Center. Dr. Chung is a retired army colonel and holds medical licenses in Texas and Maryland.- Kevin Chung，自2022年7月1日起担任海星医疗首席医疗官。钟博士于2016年至2022年担任Health Sciences军校医学系教授，并自2018年起担任医学系主任。从2014年到2020年，郑博士担任美国外科医生的重症监护顾问。从2016年到2018年，钟博士在布鲁克陆军医疗中心担任医学部主任。2015年至2016年，Chung博士担任美国陆军外科研究所研究主任，2012年至2015年担任临床试验任务区经理。从2006年到2013年，郑博士担任美国陆军烧伤中心烧伤重症监护室的医疗主任。Chung博士是一名退役陆军上校，在德克萨斯州和马里兰州持有行医执照。
- Kevin Chung has served as the Chief Medical Officer of SeaStar since July 1, 2022. Dr. Chung served as a professor in the Department of Medicine at the Uniformed Services University of the Health Sciences from 2016 to 2022, and as Chair of the Department of Medicine since 2018. From 2014 to 2020, Dr. Chung served as Critical Care Consultant to the U.S. Surgeon General. From 2016 to 2018, Dr. Chung served as Department of Medicine Chief at the Brooke Army Medical Center. From 2015 to 2016, Dr. Chung served as Director of Research at the US Army Institute of Surgical Research, and as Task Area Manager, Clinical Trial from 2012 to 2015. From 2006 to 2013, Dr. Chung served as Medical Director, Burn Intensive Care Unit at the US Army Burn Center. Dr. Chung is a retired army colonel and holds medical licenses in Texas and Maryland.